1 g daily therapy with omeprazole or high-dose H2 antagonists.

2                 Four percent took occasional H2 antagonists, and 3% were back on daily therapy.

3                        Histamine-2-receptor (H2)-antagonists as a class, were the most commonly used

4 IL-10 production, which were reversed by the H2 antagonist cimetidine, were observed in PBMC and isol

5  the H1 antagonist pyrilamine maleate or the H2 antagonist cimetidine.

6 y picrotoxinin, fipronil, strychnine, or the H2 antagonist cimetidine.

7 s who would switch to another agent when the H2-antagonist failed, 52% would change to omeprazole, wh

8 recumbent positioning, sucralfate instead of H2-antagonists for stress ulcer prophylaxis, and selecti

9 ll eligible patients, sucralfate rather than H2-antagonists in patients at low to moderate risk for g

10             Of those respondents who used an H2-antagonist initially, 48% would add sucralfate, 36% w

11 ous uncontrolled reports have suggested that H2-antagonists may possess immunomodulatory activity in

12  that range from simple solutes to histamine H2 antagonists was correlated with computed solvation fr

13 o omeprazole, whereas 67% would change to an H2-antagonist when sucralfate failed.

14 ndents who used sucralfate, 77% would add an H2-antagonist when SUP failed.